LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hi fellow warriors! New week of news. This time we also have some very positive updates about the CRISPR gene editing method. Although it doesn’t directly relate to prostate cancer, it’s something very important. Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​

Clinical Research

• Real-World Data: Treatments Seem To Work Better Than During Trials​
  A large real-world study analyzed outcomes from over 4,850 patients treated with five FDA-approved mCRPC drugs (abiraterone, enzalutamide, cabazitaxel, sipuleucel-T, and radium-223). While clinical trials showed a median survival gain of ~23 months, real-world data revealed even greater benefits—22% higher survival than trial estimates, rising to 52% among patients treated 4–6 years after drug launch. These improvements likely reflect broader patient diversity, more refined treatment strategies by physicians, and better management of side effects and sequencing of therapies. The study highlights the increasing importance of real-world evidence in guiding cancer care.
  ​
• Dr. Scott Tagawa About Combined Therapies​
  At the 2025 American Urological Association (AUA) conference, new strategies in radioligand therapy (RLT) for mCRPC were presented by Dr. Scott Tagawa. His approach uses antibody-based RLT—specifically the J591 antibody linked to actinium-225, a powerful alpha emitter—to target PSMA, a protein highly expressed in prostate cancer. Compared to small molecules, antibodies circulate longer, clear through the liver, and avoid healthy tissues like kidneys and salivary glands. Combination therapies using multiple PSMA-targeting agents or pairing RLT with androgen receptor inhibitors and immune checkpoint inhibitors showed significantly improved progression-free and overall survival, despite a slight increase in high-grade toxicities. Dr. Tagawa anticipates such combinations could become standard practice to enhance outcomes and reduce individual drug doses.
  ​

Preclinical Research

• New Nanotherapy Drugs The Undruggable​
  A new nanotherapy called SCORT (Selective Cell in ORgan Targeting) has shown promise against metastatic castration-resistant prostate cancer (mCRPC). SCORT delivers RNA-based therapeutics via lipid nanoparticles engineered to knock down HoxB13, a previously “undruggable” transcription factor central to cancer progression. These nanoparticles use an E3 aptamer to target transferrin receptor 1 (TfR1), abundant on mCRPC cells, ensuring precision delivery while sparing healthy tissue. In lab and animal studies, SCORT significantly suppressed tumor growth and metastasis, prolonged survival, and showed minimal toxicity in healthy mice. Mechanistically, it works by reprogramming gene expression, reducing cell proliferation and blood vessel formation, and disrupting metastasis-linked pathways.
  ​
• CRISPR Strikes Again​
  A major medical milestone was achieved with the first successful human use of a personalized CRISPR-based gene therapy. Designed for an infant with carbamoyl phosphate synthetase 1 (CPS1) deficiency—a rare genetic disorder causing toxic ammonia buildup—the therapy corrected the disease-causing mutation directly in the infant’s liver cells.Treated at six months, the child, KJ, showed rapid improvement, including better protein tolerance and reduced reliance on medication. This precision therapy targeted only non-reproductive cells and was built on modular components, paving the way for scalable, personalized treatments for other rare genetic diseases.
  ​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If you this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max